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Background: The process of gastric carcinogenesis still remains to be elucidated. The identification of genes related to
this process may help to reduce mortality rates through early diagnosis and the development of new anticancer
therapies. Nucleophosmin 1 (NPM1) acts in ribosome biogenesis, centrosome duplication, maintenance of genomic
stability, and embryonic development. Recently, NPM1 has been implicated in the tumorigenesis processes. Here, we
evaluated NPM1 gene and protein expression in gastric tumors and in corresponding non-neoplastic gastric samples.
Methods: NPM1 protein expression was determined by Western blot in 17 pairs of gastric tumors and corresponding
non-neoplastic gastric tissue. The protein immunoreactivity was observed in 12 tumor samples. mRNA expression was
evaluated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in 22 pairs of gastric tumors and in
matched non-neoplastic gastric tissue.
Results: NPM1 protein expression was significantly reduced in gastric cancer samples compared to matched
non-neoplastic gastric samples (P = 0.019). The protein level of NPM1 was reduced at least 1.5-fold in 35% of tumors
compared to paired non-neoplastic gastric tissue. However, NPM1 immunoreactivity was detected in neoplastic and
non-neoplastic cells, including in intestinal metaplastic, gastritis and inflammatory cells. NPM1 was mainly expressed in
nucleus and nucleolus subcellular compartments. The staining intensity and the percentage of immunoreactive cells
varied among the studied cases. The NPM1 mRNA level was reduced at least 1.5-fold in 45.5% of samples and increased
in 27.3% of samples. An inverse correlation between protein and mRNA expression was detected (r = -0.509, P = 0.037).
Intestinal-type gastric cancer presented higher mRNA levels than diffuse-type (P = 0.026). However, reduced NPM1
protein expression was associated with intestinal-type gastric cancer compared to matched non-neoplastic
gastric samples (P = 0.018). In addition, tumors from patients with known distant metastasis presented reduced NPM1
protein levels compared to tumors from patients without distant metastasis (P < 0.001).
Conclusion: Although the expression of NPM1 is heterogeneous in gastric tumors, our results suggest that NPM1
down-regulation may have a role in gastric carcinogenesis and may help in the selection of anticancer treatment
strategies.
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Gastric cancer (GC) is the fourth most common cancer
and the second leading cause of cancer-related death
worldwide [1]. Although this neoplasia is a serious pub-
lic health problem due to its high incidence and mortal-
ity, little is known about the molecular events involved
in gastric carcinogenesis.
Our group recently performed a proteomic analysis
aiming to identify proteins with a role in gastric car-
cinogenesis [2]. In this study, we observed reduced ex-
pression of nucleophosmin 1 (NPM1, also known as
B23, numatrin and NO38) in several gastric tumors
compared to non-neoplastic gastric samples by two-
dimensional electrophoresis and mass spectrometry.
NPM1 is a nucleolar phosphoprotein that shuttles con-
tinuously between the nucleus and the cytoplasm
(see review [3]). NPM1 function is not completely
known. NPM1 is a member of the nucleoplasmin fam-
ily of histone chaperones that favor DNA-histone and
nucleosome assembly in vitro and also interact with a
wide range of unfolded proteins, inducing proper fold-
ing in the active state [4]. These multifunctional pro-
teins act in ribosome biogenesis [5], centrosome
duplication [6,7], maintenance of genomic stability,
and embryonic development [8].
Not surprisingly, NPM1 has been implicated in
tumorigenesis processes. NPM1 overexpression was
described in solid tumors of diverse histological ori-
gins, including astrocytomas [9], as well as colon [10],
hepatocellular [11], bladder [12], breast [13], ovarian
[14] and prostate [15] carcinomas. Deletions and
chromosomal translocations involving the NPM1 locus
(5q35) were described in hematological malignancies
(see reviews [16,17]) and lung cancer [18]. Mutations
of NPM1 were also described in hematological malig-
nancies, and it has been suggested that NPM1-mu-
tated acute myeloid leukemia is a distinct leukemia
entity [19].
NPM1 seems to play a role as both a tumor suppres-
sor and an oncogene. For its tumor suppressor activity,
NPM1 seems to act directly and indirectly on the regu-
lation of p53 [3]. On the other hand, NPM1 is also in-
volved in transcriptional activation of some oncogenes,
such as MYC [20]. Therefore, NPM1 overexpression
leads to increased cell growth and proliferation and in-
hibits differentiation and apoptosis [3].
To our knowledge, only two studies have evaluated
NPM1 mRNA expression in a small set of human pri-
mary GC [21,22]. Thus, the role of NPM1 in gastric
carcinogenesis remains to be elucidated. In the present
study, we analyzed NPM1 mRNA and protein expres-
sion in GC and matched non-neoplastic gastric sam-
ples. We also evaluated the possible associations
between NPM1 and clinicopathological characteristics.Methods
Tissue samples
NPM1 mRNA expression was evaluated in 22 pairs of
GC samples and matched non-neoplastic gastric tissue
(>5 cm from the edge of the tumor). In 17 pairs of these
GC samples and corresponding non-neoplastic gastric
tissue, the protein expression was also evaluated. The
protein immunoreactivity was assessed in 12 tumors.
All the gastric samples were obtained from patients
who underwent gastrectomy for GC at João de Barros
Barreto University Hospital (HUJBB) in the State of
Pará, Northern Brazil, during the period from 2006 to
2010. Informed consent with approval of the ethics com-
mittee of HUJBB was obtained. All patients had negative
histories of exposure to either chemotherapy or radio-
therapy before surgery, and there was no co-occurrence
of other diagnosed cancers.
Part of the dissected tumor samples was formalin-
fixed and paraffin embedded (FFPE). Sections of FFPE
tissue were stained with hematoxylin-eosin for histo-
logical evaluation or used for immunohistochemistry
analysis (IHC). The other part of tumors and the paired
non-neoplastic tissue specimens were immediately cut
from resected stomachs, frozen in liquid nitrogen and
kept at -80°C until protein and nucleic acid extraction.
Table 1 shows the clinicopathological characteristics of
the GC samples. All samples were classified according to
Laurén [23], and tumors were staged using standard cri-
teria by TNM staging [24]. The presence of H. pylori, a
class I carcinogen, in GC and non-neoplastic samples
was detected by PCR assay. PCR for the urease gene
[25] and for the H. pylori virulence factor cytotoxin-
associated gene A (CagA) [26] was performed as previ-
ously reported using the DNA purified simultaneously
with the proteins and the mRNA. All reactions were per-
formed in duplicate. In each PCR experiment, positive
and negative controls were included. A sample was con-
sidered positive if a clear and visible band was observed
on the electrophoresis gel (2% agarose gel). In our sample,
all GC and non-neoplastic samples presented H. pylori
infection.
Protein and mRNA purification
Total protein and mRNA were simultaneously isolated
from the gastric tissue samples using the AllPrep DNA/
RNA/Protein Kit (Qiagen, Germany) according to the
manufacturer's instructions. The protein pellet was dis-
solved in a buffer containing 7 M urea, 2 M thiourea,
4% 3-[(3-cholamidopropyl) dimethylammonio]-1-propa-
nesulfonate (CHAPS), 50 mM dithiothreitol (DTT), 1%
Protease Inhibitor Cocktail (Sigma) and 0.5% each of
Phosphatase Inhibitor Cocktails 1 and 2 (Sigma-Aldrich,
USA). The protein concentration was determined by
the Bradford method (Sigma-Aldrich, USA). The RNA
Table 1 Clinicopathological characteristics NPM1 expression in gastric cancer samples
NPM1 protein NPM1 mRNA
Variable N Ratio T/N (Mean ± SD) P value N RQ (Mean ± SD) P value
Gender
Male 8 0.81 ± 0.36 0.431 12 2.47 ± 3.86 0.657
Female 9 0.67 ± 0.39 10 1.76 ± 3.43
Onset (years)
< 45 5 0.73 ± 0.48 0.973 7 0.95 ± 0.89 0.298
≥ 45 12 0.74 ± 0.34 15 2.70 ± 4.25
Tumor location
Cardia 2 0.87 ± 0.04 0.601 2 0.17 ± 0.19 0.429
Non-cardia 15 0.72 ± 0.39 20 2.34 ± 3.73
Histological subtype
Diffuse-type 4 0.97 ± 0.25 0.159 6 0.33 ± 0.28 0.026*
Intestinal-type 13 0.66 ± 0.38 16 2.83 ± 4.04
Differentiation
Moderately differentiated 8 0.72 ± 0.38 0.492 10 2.84 ± 4.14 0.990
Poorly differentiated 5 0.57 ± 0.40 6 2.81 ± 4.26
Stage
Early 4 0.66 ± 0.31 0.675 4 1.02 ± 1.05 0.472
Advanced 13 0.76 ± 0.40 17 2.54 ±4 .01
Tumor invasion
T1/T2 7 0.78 ± 0.27 0.672 9 1.61 ± 1.63 0.502
T3/T4 10 0.70 ± 0.44 12 2.73 ± 4.67
Lymph node metastasis
Absent 6 0.78 ± 0.30 0.757 7 1.48 ± 1.82 0.509
Present 11 0.71 ± 0.42 14 2.63 ± 4.31
Distant metastasis
Unknown/absent 14 0.86 ± 0.26 < 0.001a 18 1.21 ± 1.29 0.220
Present 3 0.15 ± 0.20 3 8.49 ± 7.18
T, tumor sample; N, matched non-neoplastic sample; SD, standard deviation; RQ, relative quantification – gastric tumor samples normalized by matched non-
neoplastic sample. *Differentially expressed between groups, P <0.05, using t-test for independent samples.
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Drop spectrophotometer (Kisker, Germany), and the RNA
integrity was determined by gel electrophoresis.
NPM1 protein expression by Western blot
Reduced protein (20 μg) from each sample was sepa-
rated on a 12.5% homogeneous SDS-PAGE gel and
electro-blotted to a polyvinylidene difluoride (PVDF)
membrane (Hybond-P, GE Healthcare, USA). The PVDF
membrane was blocked with phosphate-buffered saline
containing 0.1% Tween 20 and 5% low fat milk and incu-
bated overnight at 4°C with anti-NPM1 (FC-61991, 1:500,
Invitrogen, USA) and anti-β-Actin antibodies (ACTB;
Ac-74, 1:3000, Sigma-Aldrich, USA). After extensive wash-
ing, the PVDF membrane was incubated with a peroxidase-
conjugated secondary antibody for 1 hour at room
temperature. Immunoreactive bands were visualizedusing Western blotting Luminol reagent, and the images
were acquired using an ImageQuant 350 digital image
system (GE Healthcare, Sweden). ImageJ 1.43u software
(National Institutes of Health, USA) was used for gel
band quantitative densitometric analysis. ACTB was
used as a loading reference control. In each experiment,
tumor and matched non-neoplastic samples were applied
to the same gel. One of the non-neoplastic samples (refe-
rence) was applied to all gels to allow comparison among
different experiments.
NPM1 immunoreactivity by IHC
Paraffin sections from 12 different tumor samples were
subjected to IHC. Tumor tissue sections (3 or 4 mm-
thick) were deparaffinized in xylene and rehydrated in a
graded series of ethanol. After heat-induced epitope re-
trieval, the tissue sections were incubated with primary
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Neomarkes, USA). A universal peroxidase-conjugated
secondary antibody kit (LSAB System, DakoCytomation,
USA) was used for the detection system. We used 3.30-
diamino-benzidine/H2O2 (Dakocytomation, Denmark)
as the chromogen and hematoxylin as the counterstain.
Negative controls in which the primary antibody was re-
placed by bovine serum albumin (BSA) 5% in phosphate-
buffered saline (PBS) were performed in all series, and
sections of normal human amygdala tissue were used as
positive controls.
The slides were viewed by light microscopy using
a Nikon Eclipse E600 microscope (Nikon, NY, USA)
equipped with a digital camera Nikon DSM1200F (Nikon,
NY, USA). The nonstained region (white region) was se-
lected and set as background. Any staining was considered
to be a positive result, irrespective of intensity. An arbi-
trary semiquantitative score was developed to quantify
NPM1 immunoreactivity, as follows: 0, from negative to
minimal staining (< 10% of cells); 1+, for those tumors
showing a weak staining and over 10% of cells; 2+, for
those tumors presenting a moderate staining and over
10% of cells; and 3+, for those tumors presenting a
strong staining and over 10% of cells.
NPM1 mRNA expression by reverse transcription
quantitative polymerase chain reaction (qRT-PCR)
First, complementary DNA was synthesized using the
High-Capacity cDNA Archive kit (Applied Biosystems,
Poland) according to the manufacturer’s protocol. All
real-time RT-qPCR reactions were performed in tripli-
cate for both the target gene (NPM1: Hs01576587_g1,
Applied Biosystems, USA) and the internal control
(ACTB: Hs03023943_g1, Applied Biosystems, USA). The
relative quantification (RQ) of the gene expression was
calculated according to Pfaffl method [27]. A non-
neoplastic gastric tissue was designed as a calibrator for
all samples for the comparison between neoplastic and
non-neoplastic samples. In addition, the non-neoplastic
gastric tissue sample was designated as a calibrator for
each paired tumor for clinicopathological analysis.
Statistical analysis
Gene and protein expression data are shown as mean ±
standard deviation (SD) for each group. We first evalu-
ated the normal distribution of all data using the
Shapiro-Wilk normality test to determine the subse-
quent use of appropriate tests for statistical comparison.
NPM1 mRNA levels were not normally distributed and
were transformed (z-score) for analysis such that they
followed a normal distribution. Paired t-tests were per-
formed to compare the mean NPM1 expression between
non-neoplastic and tumor samples. The associations be-
tween the clinicopathological parameters and the meanNPM1 mRNA and protein expression were assessed
using t-tests for independent samples. The possible asso-
ciations between NPM1 immunoreactivity and clinico-
pathological parameters were assessed by Fisher’s exact
test. The correlation between NPM1 immunoreactivity
and mRNA or protein expression by Western blot was
analyzed by Spearman’s rank correlation test. The correl-
ation between NPM1 mRNA and protein expression by
Western blot was analyzed by Pearson’s test. For the
analyses using the t-test for independent samples and
the Pearson’s test, the NPM1 expression in tumor sam-
ples was calibrated by their matched non-neoplastic
counterpart. In all analyses, P < 0.05 was considered
significant.
Results
NPM1 protein expression was significantly reduced in
GC samples compared to matched non-neoplastic gastric
samples (0.99 ± 0.54 vs 1.39 ± 0.39, values relative to the
reference sample; P = 0.019, by paired t-test; Figure 1A).
The protein level of NPM1 was reduced at least 1.5-fold
(50% decrease in the expression) in 35% of GC samples,
and no tumor presented an increase in expression of 50%
compared to their paired non-neoplastic gastric tissue
(Figure 1B and 1C).
In all cases, the NPM1 immunoreactivity was detected
in neoplastic and non-neoplastic cells, including in in-
testinal metaplastic, gastritis and inflammatory cells
(Figure 2A-H). NPM1 was mainly expressed in nucleus
and nucleolus. Only one case presented cytoplasmatic
staining in the parietal cells (Figure 2B). The staining in-
tensity and the percentage of immunoreactive cells varied
among the studied cases (Table 2). In nuclei of tumor
cells, NPM1 immunoreactivity score ranged from 0 to 2,
with 41.7% cases presenting score 0. In nucleoli of tumor
cells, 5 of 12 cases (41.7%) presented score 0 and 7 of 12
(58.3%) presented score 2. The score of NPM1 immunore-
activity in the nucleoli of tumor cells was inversely cor-
related with the protein expression by Western blot
(r = -0.693, p = 0.039; by Spearman’s correlation).
The NPM1 mRNA expression did not differ between
GC and matched non-neoplastic gastric samples (0.29 ±
0.41 vs 0.39 ± 0.42, values relative to a calibrator non-
neoplastic sample; P = 0.33, by paired t-test; Figure 1D).
The NPM1 mRNA level was reduced at least 1.5-fold
in 45.5% of samples and increased in 27.3% of samples
(Figure 1E). A moderate inverse correlation was ob-
served between the relative quantifications of NPM1
protein and mRNA levels (r = -0.509; P = 0.037, by
Pearson’s correlation; Figure 1F).
The intestinal-type GC presented higher NPM1 mRNA
levels than diffuse-type GC (P = 0.026, by t-test; Table 1).
The mRNA expression was at least 50% reduced in all
diffuse-type. In the intestinal-type, the mRNA expression
Figure 1 Expression of NPM1 in gastric samples. (A) protein expression normalized by ACTB and calibrated by the level of a reference
sample; (B) the ratio of NPM1 protein expression between tumor and matched non-neoplastic samples; (C) Western blot using anti-NPM1 and
anti-ACTB antibodies in representative gastric tumors and their matched non-neoplastic counterparts; (D) mRNA expression normalized by ACTB
and calibrated by a non-neoplastic gastric tissue; (E) relative quantification of NPM1 mRNA expression, in which gastric tumors samples were
calibrated by the matched non-neoplastic tissue; (F) relationship between the relative quantification of NPM1 protein and mRNA levels, in which
non-neoplastic samples were used as reference for each matched tumor. T: tumor samples; N: non-neoplastic samples; RQ: Relative quantification.
*Reference sample in Western blot gels.
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in 37.5% in relation to their matched non-neoplastic
counterpart. On the other hand, the NPM1 protein level
did not differ between diffuse-type and intestinal-type GC.
However, intestinal-type GC presented a significant reduc-
tion of NPM1 protein expression compared to matched
non-neoplastic gastric samples (0.94 ± 0.58 vs 1.41 ± 0.42,
P = 0.018, by paired t-test). In addition, the protein level of
NPM1 was reduced at least 1.5-fold in 46.2% of intestinal-
type GC and in no case of diffuse-type GC.
Tumors from patients with known distant metastasis
showed reduced NPM1 protein expression compared to
tumors from patients without distant metastasis (P <
0.001, by t-test; Table 1). No association between NPM1
expression and any other clinicopathological characteris-
tics was found.
Discussion
NPM1 is a multifunctional protein. The first proposed role
of NPM1 was in the regulation of cell growth, proliferation
and transformation because its expression increases in
response to mitogenic stimuli and is up-regulated in
highly proliferative and malignant cells. However, se-
veral recent studies have demonstrated that NPM1 has
both proliferative and growth-suppressive roles in the
cell (see review [3]).In the present study, NPM1 protein expression was sig-
nificantly down-regulated in GC, which supports its role
as a tumor suppressor. One NPM1 target is cyclin-
dependent kinase inhibitor 2A (CDKNA2) alternate read-
ing frame protein (ARF; also known as p14ARF in
humans, and p19Arf in the mouse). ARF protein is in-
volved in cell-cycle arrest and apoptotic processes through
inhibition of MDM2 (E3 ubiquitin-protein ligase, a nega-
tive regulator of p53) and, therefore, stabilization of p53
[28]. NPM1 acts in the stabilization of ARF within the nu-
cleolus by protecting it from both proteasome-dependent
and proteasome-independent degradation. It has been
suggested that NPM1 loss of function could lead to an ac-
celeration of tumorigenesis owing to the destabilization
and inactivation of ARF, which is known to inhibit cell
proliferation through both p53-dependent and p53-
independent mechanisms [3,29], in agreement with a po-
tential tumor-suppressor role for NPM1.
The down-regulation of NPM1 was associated with
known distant metastasis in patients with GC, suggest-
ing that low levels of NPM1 protein expression may be a
marker of poor prognosis in GC if validated in larger
clinical study sets. Reduced NPM1 protein level was pre-
viously associated with poor outcome in some subtypes
of breast cancer [30]. On the other hand, NPM1 overex-
pression was associated with the presence of distant
Figure 2 Immunohistochemical analysis of NPM1 in gastric samples. (A) NPM1 staining in normal gastric mucosa (400×); (B) cytoplasmatic
NPM1 staining in parietal cells (400×); (C) NPM1 immunoreactivity in inflammatory cells (400×); (D) NPM1 staining in intestinal metaplastic cells
(400×); (E) minimal NPM1 staining in a poorly differentiated tumor (400×); (F) weak NPM1 staining in a poorly differentiated tumor (400×); (G)
moderate NPM1 staining in a moderately differentiated tumor (400×); (H) moderate NPM1 staining in a diffuse-type tumor (400×).
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Table 2 Immunohistochemistry analysis in gastric tumors
Case Histological subtype Differentiation Stage % of stained tumor cells Location Intensity of staining Score
1 Intestinal-type Moderately differentiated 1 60% Nucleus Moderate 2
Nucleolus Moderate 2
2 Intestinal-type Poorly differentiated 4 < 10% Nucleus Weak 0
Nucleolus Moderate 0
3 Intestinal-type Moderately differentiated 4 40% Nucleus Weak 1
Nucleolus Moderate 2
4 Intestinal-type Moderately differentiated 1 20% Nucleus Moderate 2
Nucleolus Moderate 2
5* Intestinal-type Moderately differentiated 1 40% Nucleus Weak 1
Nucleolus Moderate 2
6 Intestinal-type Poorly differentiated 3 < 10% Nucleus Weak 0
Nucleolus Weak 0
7 Intestinal-type Moderately differentiated 1 < 10% Nucleus Weak 0
Nucleolus Weak 0
8 Intestinal-type Moderately differentiated 3 < 10% Nucleus Weak 0
Nucleolus Weak 0
9 Intestinal-type Moderately differentiated 4 20% Nucleus Weak 1
Nucleolus Moderate 2
10 Intestinal-type Moderately differentiated 2 < 10% Nucleus Weak 0
Nucleolus Weak 0
11 Intestinal-type Poorly differentiated 3 40% Nucleus Weak 1
Nucleolus Moderate 2
12 Diffuse-type Not applied 3 20% Nucleus Moderate 2
Nucleolus Moderate 2
*This patient presented strong cytoplasmatic immunoreactivity in normal parietal cells (score = 3).
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depend on cellular and genetic context. The interaction
between NPM1 and MYC may be one of the pathways
by which the loss of NPM1 contributes to the develop-
ment of metastasis. The lack of a functional NPM1 was
previously associated with increased levels of MYC [32].
MYC is a key oncogene in gastric carcinogenesis (see re-
view [33]), and the overexpression or amplification of
the MYC locus was previously reported in GC samples
and preneoplastic gastric lesions [34-41]. In our popula-
tion, MYC overexpression was previously associated
with the presence of distant metastasis [42]. Moreover,
the three tumors of patients with distant metastasis pre-
sented MYC immunoreactivity (data not shown).
Here, we observed that NPM1 presented nuclear and
nucleolar location. Previous studies showed that NPM1
is a predominantly nucleolar protein, however, a fraction
can also be detected in the nucleoplasm (see review
[43]). Although the sample size is small, an inverse cor-
relation between nucleoli immunoreactivity and the pro-
tein expression (total expression) by Western blot was
observed. This finding may be in part to the key role ofNPM1 in ribosome biogenesis. In both subcellular com-
partments, the NPM1 immunoreactivity presented a large
inter- and intra-tumor heterogeneity. The NPM1 expres-
sion heterogeneity in GC cells may complicate the devel-
opment of diagnostic tests or treatments targeting the
NPM1. Efforts to pharmacologically target NPM1 for can-
cer therapy might be difficult, due to the fact that its func-
tion is likely to be tightly regulated to avoid the possibly
detrimental consequences of its decreased or increased
function [3].
The NPM1 immunoreactivity was also heterogeneous
in intestinal metaplastic, gastritis and inflammatory cells,
which are commonly observed in GC patients. NPM1
may also act as an alarmin in the immune system [44].
In macrophages, NPM1 negatively regulates cytokine
and chemokine gene expression and their secretion [45].
We hypothesized that the NPM1 expression in tumor
cells is modulated in response to microenvironmental
stimuli.
We also demonstrated that NPM1 mRNA expression
was inversely correlated with protein expression, which
suggests that post-translational mechanisms may be
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studies demonstrated that NPM1 protein is modified by
ubiquitylation [46-49], which may lead to its depletion
despite the elevated mRNA transcription. Proteins make
up the cellular machinery and play major roles in most
biological processes. Thus, direct assessment of protein
levels may often be more informative of the cellular state
than analysis of mRNA levels [50]. Protein expression is
subject to complex control and is only partly determined
by accumulation and degradation of the corresponding
mRNAs [51,52]; it is suggested that 20–60% of the vari-
ation in steady-state protein abundances is attributable
to mRNA levels [53]. It has been speculated that tran-
scriptional bursts, observed to increase variance in
mRNA abundance, may be buffered by long protein
half-lives [54].
In addition, NPM1 mRNA expression did not differ
between tumors and non-neoplastic samples. Although
approximately 45% of tumors presented reduced mRNA
expression, about 27% of GC presented more than 1.5-
fold increased expression compared to matched non-
neoplastic tissue. To our knowledge, only two previous
studies evaluated NPM1 mRNA in gastric tumors by
Northern blot. Tanaka et al. [21] reported that 2 of 3 tu-
mors presented hybridization with NPM1 probe, which
was not observed in any of the non-neoplastic samples.
You et al. [22] demonstrated that 6 of 7 GC samples pre-
sented increased expression compared to non-neoplastic
gastric tissue. However, the present study used RT-qPCR,
the most sensitive method for detection and quantification
of mRNA expression. Additionally, we evaluated a larger
number of samples, which may better reflect the hetero-
geneity of gastric tumors.
Moreover, we observed that intestinal-type GC pre-
sented higher mRNA levels than diffuse-type GC, con-
firming that these two histological GC subtypes follow
different genetic pathways and may be two distinct en-
tities [55]. Although NPM1 mRNA seems to be higher
in intestinal-type GC, this subtype showed relatively
lower levels of NPM1 protein expression compared to
the non-neoplastic samples, which reinforces the in-
verse correlation between NPM1 protein and mRNA
expression.Conclusions
We demonstrated that NPM1 down-regulation may have
a role in gastric carcinogenesis, especially in intestinal-
type GC and in tumors from patients with distant me-
tastasis. However, NPM1 expression presented a large
inter- and intra-tumor heterogeneity, which might com-
plicate the development of diagnostic tests or treatments
targeting the NPM1. On the other hand, NPM1 protein
down-regulation may help in the selection of anticancertreatment strategies based on a better understanding of
the pathways deregulated in GC.
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